Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

IDL Biotech: Reiterating Our Fair Value

2020-04-24

10:37

LS

Ludvig Svensson

Redeye reiterate its Base case valuation of SEK 5 following IDL Biotech’s Q1 report despite a significant sales drop expected in Q2 in the wake of the corona crisis. After speaking with management, we feel a growing conviction that the effect will be temporary and that the growth story will continue once the dust has settle, most likely in Q4.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers